Seeking Alpha

Viropharma (VPHM +4.3%) gets a lift today from a valuation upgrade to Overweight at JPMorgan...

Viropharma (VPHM +4.3%) gets a lift today from a valuation upgrade to Overweight at JPMorgan with a price target of $32 a share. Analyst Brian Abrahams thinks the competitive threats to VPHM's Angioedema treatment Cinryze have been overstated relative to its peers, noting that although some early-stage treatments by its competitors are "worth keeping an eye on," they have characteristics which make them a less-attractive alternative.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs